Crossmark

Budesonide treatment for microscopic colitis from immune checkpoint inhibitors

Crossref DOI link: https://doi.org/10.1186/s40425-019-0756-0

Published Online: 2019-11-07

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hughes, Michael S.

Molina, Gabriel E.

Chen, Steven T.

Zheng, Hui

Deshpande, Vikram

Fadden, Riley

Sullivan, Ryan J.

Dougan, Michael https://orcid.org/0000-0001-9266-2009
Funding

Funding for this research was provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (1K08DK114563-01)

American Gastroenterological Association (Research Scholars Award)
License Information

Text and Data Mining valid from 2019-11-07
More Information

Article History

Received: 25 July 2019

Accepted: 20 September 2019

First Online: 7 November 2019

Ethics approval and consent to participate

: NA

: Patient records were accessed and analyzed through a protocol approved by the Partners Institutional Review Board that waved patient consent.

: V.D. receives research support from Advanced cell Diagnostics and is a consultant for Agios. R.J.S. receives grant funding from Amgen and Merck, and consulting/advising fees from Amgen, Merck, Novartis, BMS, Array BioPharma, Replimmune, Compugen, Takeda, and Genentech, and a financial relationship with Boehringer Ingelheim. M.D. receives research funding from Novartis, and has received consulting fees from Genentech-Roche, and Tillotts Pharma. All other authors declare no competing interests.